MCM
LUMO

Moore Capital Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Moore Capital Management’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-11,111
Closed -$811K – 323
2017
Q4 		$811K Buy
11,111
+5,555
+100% +$459K 0.01% 219
2017
Q3 		$509K Buy
+5,556
New +$426K 0.01% 208

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Moore Capital Management's LUMO Position: Q1 2018 in Review

Moore Capital Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2018, closing a stake of 11,111 shares — an estimated $811K sold.

Moore Capital Management first reported a position in LUMO in Q3 2017 and held it in 2 quarters. The position peaked at $811K in Q4 2017. 126 funds tracked by Wall St. Rank hold LUMO as of Q1 2018.

  • Moore Capital Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Moore Capital Management sold 11,111 Lumos Pharma, Inc. Common Stock shares in Q1 2018, an estimated $811K.
  • Moore Capital Management first reported a position in Lumos Pharma, Inc. Common Stock in Q3 2017 and held it in 2 quarters.
  • Moore Capital Management's Lumos Pharma, Inc. Common Stock position peaked at $811K in Q4 2017.
  • 126 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2018.

Based on Moore Capital Management's 13F filing for Q1 2018, filed 15 May 2018.